Prostate Cancer

Treating patients with metastatic castration-resistant prostate cancer with radium-223 also allowed patients to receive subsequent therapies such as chemotherapy.

Lynparza plus abiraterone was approved by the FDA for the treatment of patients with deleterious or suspected BRCA-mutated metastatic castration-resistant prostate cancer.

The approval of Posluma will help clinicians determine the extent of disease in men with prostate cancer and possible management options.

My husband is "that guy" who always takes care of everyone else, so his recent cancer scare was unfathomable.

Men with low-risk prostate cancer can usually safely forego treatment as long as they continue to monitor their disease with their clinicians, an expert said.

Finding humor in cancer has helped me cope.

Erleada showed promising results in patients with metastatic castration-sensitive prostate cancer when compared with Xtandi and Zytiga.

A dose reduction of Erleada may result in fewer skin-related side effects for men with advanced prostate cancer — but only for those with a smaller body size, research showed.

Men with metastatic hormone-sensitive prostate cancer treated with Nubeqa, androgen-deprivation therapy and docetaxel had reductions in PSA levels that were associated with improved overall survival and a prolonged time to PSA progression.

Extended-duration Nubeqa reduced the risk of death in patients with nonmetastatic castration-resistant prostate cancer, study results showed.

Patients with metastatic castration-resistant prostate cancer treated with radioligand therapy, a form of targeted therapy, had improvements in PSA levels and survival with favorable side effect profiles.

From talk show host Jerry Springer’s death to “The Young and the Restless” star announcing a cancer diagnosis, here is what’s happening in the oncology space this week.

The makers of a new treatment for metastatic, castration-resistant prostate cancer are working to bring it to patients “as quickly as possible.”

From ‘Pokémon’ actor James Carter Cathcart stepping away from the show to undergo cancer treatment to Ahmad Jamal and Otis Redding III dying of cancer, here’s what’s happening in the oncology space this week.

A prostate cancer expert lends insight to the nationwide Pluvicto shortage, and what eligible patients can do.

Researchers determined that mortality rates did not differ in men with localized prostate cancer if they underwent active monitoring, prostatectomy or radiotherapy.

From the San Diego Padres’ coach missing Opening Day for colon cancer surgery to WWE star Alexa Bliss sharing her skin cancer experience and warning people against tanning beds, here’s what’s happening in the oncology space this week.

The phase 3 ARASTEP trial will investigate Nubeqa plus androgen-deprivation therapy in certain patients with hormone-sensitive prostate cancer.

Gay and bisexual men with prostate cancer may have different needs that need to be addressed with health care providers as they go through treatment and beyond.

Since I’ve become a patient and advocate, my social media algorithm now mostly shows cancer-related content. Here’s an open letter to said algorithm, or as I call it, “Algo.”

Long-term follow-up of Nubeqa for nonmetastatic castration-resistant prostate cancer showed that the drug was safe and effective in treating this patient population.

One of the trials investigating Keytruda has been discontinued because the drug did not significantly improve outcomes in patients with prostate cancer.

With a wink and wearing a mischievous smile, my friend “Charley” likes to relate how he learned about his diagnosis of prostate cancer several years ago.

From comedian Chris Tucker teaming up with a nonprofit to educate Black men on their prostate cancer risk to Leeane Hainby and Rep. Jamie Raskin providing updates on their cancer treatment, here’s what’s happening in the cancer space this week.

An expert explains what patients with low-grade prostate cancer can expect when undergoing genomic testing — and why the procedure is important.

The combination demonstrated survival benefit in patients with metastatic hormone-sensitive prostate cancer, regardless of risk or volume of disease.

From Senator Bob Casey undergoing prostate cancer surgery to a man giving away his Superbowl tickets to a good friend with stage 4 cancer, here’s what is happening in the oncology space this week.

The administration of Pluvicto within six months of radium-223 treatment proved to be safe and efficacious in patients with metastatic castration-resistant prostate cancer, research showed.

Patients treated with Nubeqa were less likely to develop disease metastasis or discontinue treatment 6 to 18 months after ARI course start compared to Xtandi or Erleada, according to data presented at ASCO GU.